Institution |
Study Title |
|
CUHK |
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) |
Click for Details |
CUHK |
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib |
Click for Details |
CUHK |
A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Click for Details |
CUHK |
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer |
Click for Details |
CUHK |
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation (CJDQ4433A12101) |
Click for Details |
CUHK |
A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies |
Click for Details |
CUHK |
A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors,Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) |
Click for Details |
CUHK |
A Phase 1/2, Open-Label, Multi-Center, First-in-HumanStudy of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity ofTPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3Rearrangements |
Click for Details |
CUHK |
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Click for Details |
CUHK |
A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors with KRAS p.G12C Mutation (Codebreak 105) |
Click for Details |
CUHK |
A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors |
Click for Details |
CUHK |
A First in-human, phase 1/2 study of CFI-402411, hematopoietic progenitor kinase-1 (HPK1) inhibitor, as a single agent and in combination with pembrolizumab in subjects with advanced solid malignancies |
Click for Details |
CUHK |
(ACT029) A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (LOXO-IDH-20002) |
Click for Details |